Skip to search boxSkip to navigationSkip to main content

The impact of outdoor pollution and extreme temperatures on asthma-related outcomes: A systematic review for the EAACI guidelines on environmental science for allergic diseases and asthma

  • Transylvania University
    ,
  • CIBER de Epidemiología y Salud Pública (CIBERESP)
    ,
  • University of Montpellier and INSERM
    ,
  • University of Florence
    ,
  • CIBER Epidemiología y Salud Pública (CIBERESP)
    ,
  • Allergy and Clinical Immunology Unit San Giovanni di Dio Hospital
Research Output: Contribution to journal Review article Peer-review

Open access

Publication Information

Output type

Research Output: Contribution to journal Review article Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 1725-1760 (36 pages)

Journal (Volume, Issue Number)

Allergy: European Journal of Allergy and Clinical Immunology (Volume 79, Issue 7)

Publication milestones

  • Accepted/In press - 2024
  • Published - 07/2024

Publication status

Published - 07/2024

ISSN

0105-4538

Publication IDs

  • Scopus: 85184248564
  • PubMed: 38311978

Abstract

Air pollution is one of the biggest environmental threats for asthma. Its impact is augmented by climate change. To inform the recommendations of the EAACI Guidelines on the environmental science for allergic diseases and asthma, a systematic review (SR) evaluated the impact on asthma-related outcomes of short-term exposure to outdoor air pollutants (PM2.5, PM10, NO2, SO2, O3, and CO), heavy traffic, outdoor pesticides, and extreme temperatures. Additionally, the SR evaluated the impact of the efficacy of interventions reducing outdoor pollutants. The risk of bias was assessed using ROBINS-E tools and the certainty of the evidence by using GRADE. Short-term exposure to PM2.5, PM10, and NO2 probably increases the risk of asthma-related hospital admissions (HA) and emergency department (ED) visits (moderate certainty evidence). Exposure to heavy traffic may increase HA and deteriorate asthma control (low certainty evidence). Interventions reducing outdoor pollutants may reduce asthma exacerbations (low to very low certainty evidence). Exposure to fumigants may increase the risk of new-onset asthma in agricultural workers, while exposure to 1,3-dichloropropene may increase the risk of asthma-related ED visits (low certainty evidence). Heatwaves and cold spells may increase the risk of asthma-related ED visits and HA and asthma mortality (low certainty evidence).

Funding Details

All the other authors report no COIs in relation to this article. Ioana Agache reports Deputy Editor of Allergy journal. Marek Jutel reports personal fees outside of submitted work from Allergopharma, ALK‐Abello, Stallergenes, Anergis, Allergy Therapeutics, Leti, HAL, GSK, Novartis, Teva, Takeda, Chiesi, Pfizer, Regeneron, Astra‐Zeneka, Lallemand, Shire, Celltrion Inc., Genentech, Roche, Verona, Lek Pharmaceuticals, Arcutis Biotherapeutics, and FAES FARMA. Kari Nadeau reports grants from National Institute of Allergy and Infectious Diseases (NIAID), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Environmental Health Sciences (NIEHS), and Food Allergy Research & Education (FARE); Stock options from IgGenix, Seed Health, ClostraBio, Cour, Alladapt; Advisor at Cour Pharma; Consultant for Excellergy, Red tree ventures, Before Brands, Alladapt, Cour, Latitude, Regeneron, and IgGenix; Cofounder of Before Brands, Alladapt, Latitude, and IgGenix; National Scientific Committee member at Immune Tolerance Network (ITN), and National Institutes of Health (NIH) clinical research centers; patents include, “Mixed allergen com‐position and methods for using the same,” “Granulocyte‐based methods for detecting and monitoring immune system disorders,” and “Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders”. Fan Chung has received honoraria for participating in Advisory Board meetings of GSK, AZ, Roche, Merck, Shionogi, and Reckitt‐Beckinson, for speaking engagements for Novartis, GSK and AZ, and for participating on the Scientific Advisory Board of the Clean Breathing Institute supported by Haleon. He has received research funding through his institution, Imperial College London, from UK Research and Innovation and the US National Institute for Environmental Health Sciences on air pollution and respiratory health, and on precision medicine for asthma, from GSK on eosinophils and asthma, and from Merck on ATP and chronic cough. Santiago Quirce has been on advisory boards for and has received speaker's honoraria from Allergy Therapeutics, AstraZeneca, GlaxoSmithKline, Novartis, Chiesi, Mundipharma, and Sanofi. Stephen Holgate reports being member of Dyson SAB on clean air, cofounder, and NEB member of Synairgen spin‐out respiratory company developing inhaled antiviral Interferon beta, advisor to Healthy Air Technology (Air purifiers), special Advisor to the Royal College of Physicians on Air Quality, UKRI Clean Air Champion, and Chair of MRC Joint Steering Committee EMINENT (Experimental Medicine Initiative to Explore New Therapies). CC, JS, DR, YR, WN, YS, YC, MR, JCV, IS, and PA work for Centro Cochrane Iberoamericano; the center received funding for conducting the systematic reviews of the evidence.
FundersFunding numbers
National Scientific Committee
-
NIH
-
NHLBI
-
NIAID
-
NIEHS
-
FARE
-
IgGenix
-

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Mentions
3
Captures
46
Citations
36

Sustainable Development Goals

  • SDG 13 - Climate Action
    SDG 13 Climate Action